NanoViricides (NYSE-A:NNVC), a clinical-stage company developing broad-spectrum antiviral drugs, will present at Biotech Showcase 2025 in San Francisco, coinciding with the JP Morgan Life Sciences Conference.
President Dr. Anil R. Diwan will discuss the company’s pipeline, including Phase II-ready NV-387, which mimics a host-side feature exploited by most viruses, offering potential akin to penicillin for bacterial infections.
The presentation is on January 14, 2025, at 2:30 PM PT.